Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment

Drancourt et al., Viruses, doi:10.3390/v13050890
May 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Retrospective 3,737 patients in France, showing lower risk of persistent viral shedding with HCQ+AZ treatment.
Drancourt et al., 12 May 2021, peer-reviewed, 11 authors, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
This PaperHCQAll
SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment
Michel Drancourt, Sébastien Cortaredona, Cléa Melenotte, Sophie Amrane, Carole Eldin, Bernard La Scola, Philippe Parola, Matthieu Million, Jean-Christophe Lagier, Didier Raoult, Philippe Colson
Viruses, doi:10.3390/v13050890
SARS-CoV-2 nasopharyngeal shedding contributes to the spread of the COVID-19 epidemic. Among 3271 COVID-19 patients treated at the
This was not our situation, where only one patient had lymphoma and another had immunosuppression following kidney transplantation. In addition, several cases of viral shedding beyond 90 days occurred in patients who received treatments with convalescent plasma and/or remdesivir [17, 18] . These situations were not encountered in this series, as no patient received remdesivir or convalescent plasma and the figures reported here were observed in the context of standardized care, including the prescription of hydroxychloroquine and azithromycin treatment. It is noteworthy that almost one quarter of the 34 persistent shedders reported here did not receive the combination of hydroxychloroquine and azithromycin, a prevalence significantly higher than that in short shedders. This standardized care notably differed in other series reporting a higher proportion of persistent shedders, yet populations may not have been similar, bringing into question the impact of combination of hydroxychloroquine plus azithromycin at the dosage prescribed in reducing the time of SARS-CoV-2 nasopharyngeal shedding. This reported series mirrors the first COVID-19 epidemic in our region, which was caused by SARS-CoV-2 of clades 20A, 20B and 20C. Accordingly, based on next-generation population sequencing we did not observe any genotype pattern in any of the 21 patients whose viral genome could be explored. Further ultradeep sequencing of paired early and late nasopharyngeal swabs in the 34 patients..
References
Amrane, Tissot-Dupont, Doudier, Eldin, Hocquart et al., Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France,-January 31st to March 1st, 2020: A respiratory virus snapshot, Travel Med. Infect. Dis, doi:10.1016/j.tmaid.2020.101632
Avanzato, Matson, Seifert, Pryce, Williamson et al., Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer, Cell, doi:10.1016/j.cell.2020.10.049
Aydillo, Gonzalez-Reiche, Aslam, Van De Guchte, Khan et al., Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer, N. Engl. J. Med, doi:10.1056/NEJMc2031670
Baang, Smith, Mirabelli, Valesano, Manthei et al., Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient, J. Infect. Dis, doi:10.1093/infdis/jiaa666
Buckland, Galloway, Nic Fhogartaigh, Meredith, Provine et al., Treatment of COVID-19 with remdesivir in the absence of humoral immunity: A case report, Nat. Commun, doi:10.1038/s41467-020-19761-2
Canarutto, Del Barba, Di Frenna, Del Tedesco, Pajno et al., Prolonged asymptomatic SARS-CoV-2 infection in a child receiving immunosuppressive therapy, Pediatr. Pulmonol, doi:10.1002/ppul.24983
Cevik, Tate, Lloyd, Maraolo, Schafers et al., SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: A systematic review and meta-analysis, Lancet Microbe, doi:10.1016/S2666-5247(20)30172-5
Chen, Zhu, Hong, Zeng, He et al., Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.06.091
Choi, Choudhary, Regan, Sparks, Padera et al., Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host, N. Engl. J. Med, doi:10.1056/NEJMc2031364
Colson, Levasseur, Gautret, Fenollar, Hoang et al., Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: An investigational study, Travel Med. Infect. Dis, doi:10.1016/j.tmaid.2021.101980
Devine, Maxwell, Haynes, Macbrayne, Boguniewicz, Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19, J. Pediatr. Hematol, doi:10.1097/MPH.0000000000002014
Fontana, Villamagna, Sikka, Mcgregor, Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature, Infect. Control Hosp. Epidemiol, doi:10.1017/ice.2020.1273
Fournier, Colson, Levasseur, Gautret, Luciani et al., Genome sequence analysis enabled deciphering the atypical evolution of COVID-19 in
Gautret, Lagier, Parola, Meddeb, Mailhe et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.105949
Helleberg, Niemann, Moestrup, Kirk, Lebech et al., Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy, J. Infect. Dis
Hensley, Bain, Jacobs, Nambulli, Parikh et al., Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study, Clin. Infect. Dis, doi:10.1093/cid/ciab072
Hueso, Pouderoux, Péré, Beaumont, Raillon et al., Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19, Blood, doi:10.1182/blood.2020008423
Jaafar, Aherfi, Wurtz, Grimaldier, Van Hoang et al., Correlation Between 3790 Quantitative Polymerase Chain Reaction-Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates, Clin. Infect. Dis, doi:10.1093/cid/ciaa1491
Kemp, Collier, Datir, Ferreira, Gayed et al., Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation, medRxiv, doi:10.1101/2020.12.05.20241927v3.full
Khatamzas, Rehn, Muenchhoff, Hellmuth, Gaitzsch et al., Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host, medRxiv, doi:10.1101/2021.01.10.20248871
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med. Infect. Dis, doi:10.1016/j.tmaid.2020.101791
Levasseur, Delerce, Caputo, Brechard, Colson et al., Genomic diversity and evolution of coronavirus (SARS-CoV-2) in France from 309 COVID-19-infected patients, bioRxiv
London, Boutboul, Lacombe, Pirenne, Heym et al., Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy, J. Clin. Immunol
Malsy, Veletzky, Heide, Hennigs, Gil-Ibanez et al., Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19), Clin. Infect. Dis, doi:10.1093/cid/ciaa1637
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med. Infect. Dis, doi:10.1016/j.tmaid.2020.101738
Myrstad, Ihle-Hansen, Tveita, Andersen, Nygård et al., National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19-A prospective cohort study, Scand. J. Trauma Resusc. Emerg. Med, doi:10.1186/s13049-020-00764-3
Nakajima, Ogai, Furukawa, Arai, Anan et al., Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient, J. Infect. Chemother, doi:10.1016/j.jiac.2020.12.001
Pedro, Silva, Magalhães, Cavadas, Rocha et al., Dynamics of a Dual SARS-CoV-2 Lineage Co-Infection on a Prolonged Viral Shedding COVID-19 Case: Insights into Clinical Severity and Disease Duration, Microorganisms, doi:10.3390/microorganisms9020300
Scola, Le Bideau, Andreani, Hoang, Grimaldier et al., Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards, Eur. J. Clin. Microbiol. Infect. Dis, doi:10.1007/s10096-020-03913-9
Sepulcri, Dentone, Mikulska, Bruzzone, Lai et al., The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-A case study, MedRxiv, doi:10.1101/2021.01.23.21249554
Tarhini, Recoing, Bridier-Nahmias, Rahi, Lambert et al., Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection, J. Infect. Dis, doi:10.1093/infdis/jiab075
Tzarnas, Kramer, Alberti, Chan, Alam Khan et al., Convalescent Plasma Therapy in a Refractory Case of COVID-19 in an Immunocompromised Patient, Crit. Care Med, doi:10.1097/01.ccm.0000726612.71471.eb
Wei, Liu, Zhao, Chen, Prolonged shedding of SARS-CoV-2 in an elderly liver transplant patient infected by COVID-19: A case report, Ann. Palliat. Med, doi:10.21037/apm-20-996
Widders, Broom, Broom, SARS-CoV-2: The viral shedding vs infectivity dilemma, Infect. Dis. Health
Zheng, Peng, Xu, Zhao, Liu et al., Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis, J. Infect, doi:10.1016/j.jinf.2020.04.021
Zhu, Zhang, Wang, Li, Yang et al., A Novel Coronavirus from Patients with Pneumonia in China, N. Engl. J. Med, doi:10.1056/NEJMoa2001017
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit